Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study

被引：0
|
作者：
Guo, Weijian
Bi, Feng
Dong, Jian
Jin, Chuan
Niu, Zuoxing
Wang, Yusheng
Sun, Meili
Wang, Teng
Yu, Dajun
He, Yifu
Zhang, Ruixing
Yin, Xianli
Feng, Wenlei
Zhang, Meijiang
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Gastrointestinal Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, Dept Abdominal Oncol, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
[4] Guangzhou Med Univ, Affiliated Tumor Hosp, Guangzhou, Peoples R China
[5] Shandong Canc Hosp, Jinan, Peoples R China
[6] Shanxi Canc Hosp, Taiyuan, Peoples R China
[7] Shandong First Med Univ, Dept Oncol, Cental Hosp, Dept Oncol, Jinan, Peoples R China
[8] Jiangnan Univ, Affiliated Hosp, Dept Oncol, Wuxi Peoples Hosp 4, Wuxi, Jiangsu, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Surg Oncol, Bengbu, Peoples R China
[10] Anhui Prov Canc Hosp, Hefei, Peoples R China
[11] Hebei Med Univ, Hebei Canc Hosp, Hosp 4, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China
[12] Hunan Canc Hosp, Changsha, Peoples R China
[13] Qilu Pharmaceut Co Ltd, Dept Oncol, Jinan, Peoples R China
[14] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Peoples R China
[15] Qilu Pharmaceut Co Ltd, Clin Res Ctr, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [22] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.
    Qin, Shukui
    Li, Jin
    Zhong, Haijun
    Jin, Chuan
    Chen, Lili
    Yuan, Xianglin
    Fan, Qingxia
    Chen, Kehe
    Cao, Peiguo
    Xiao, Jianjun
    Jiang, Da
    Zhang, Tao
    Zhang, Hongyu
    Wang, Xicheng
    Wang, Wei
    Wang, Qingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
    Zhang, Bo
    Song, Yan
    Luo, Suxia
    Yin, Xianli
    Li, Enxiao
    Wang, Hui
    He, Yifu
    Liu, Zhihui
    Fan, Qingxia
    Liang, Xinjun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Nong
    Zhang, Shu
    Zhuang, Zhixiang
    Zhang, Jingdong
    Kou, Xiaoge
    Wang, Fen
    Zhu, Xiaodong
    Zeng, Shan
    Wang, Ke
    Zhong, Haijun
    Li, Shengmian
    Bai, Yuxian
    Yu, Junyan
    Dou, Yiwei
    Ma, Taiyang
    Liu, Qian
    Huang, Jing
    CELL REPORTS MEDICINE, 2023, 4 (12)
  • [25] Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC).
    Salem, Mohamed E.
    Andre, Thierry
    El-Refai, Sherif Mohamed
    Kopetz, Scott
    Tabernero, Josep
    Sinicrope, Frank A.
    Tie, Jeanne
    George, Thomas J.
    VanCutsem, Eric
    Mauer, Elizabeth
    Lonardi, Sara
    Overman, Michael J.
    Foureau, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana
    Mangan, Niamh
    Miller, Rowan E.
    Pikiel, Joanna
    Mirza, Mansoor R.
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer
    Tinker, Anna V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
  • [27] Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
    Berton-Rigaud, D.
    Pautier, P.
    Lorusso, D.
    Gennigens, C.
    Gladieff, L.
    Kryzhanivska, A.
    Bowman, J.
    Tian, C.
    Cornfeld, M.
    Van Gorp, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [28] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
    Cohen, Romain
    Bennouna, Jaafar
    Henriques, Julie
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Vernerey, Dewi
    Menu, Yves
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [29] Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study
    Samuel, L.
    Miller, R.
    Ross, P.
    Arkenau, T.
    Antony, G.
    Veneris, J.
    Rule, J.
    Starling, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S73 - S74
  • [30] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
12345